Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor.
Terlizzi V, Fevola C, Presti S, Castaldo A, Daccò V, Claut L, Sepe A, Majo F, Casciaro R, Esposito I, Vitullo P, Salvi M, Troiani P, Ficili F, Parisi GF, Pantano S, Costa S, Leonetti G, Palladino N, Taccetti G, Bonomi P, Salvatore D. Terlizzi V, et al. Among authors: taccetti g. J Pediatr. 2024 Nov;274:114176. doi: 10.1016/j.jpeds.2024.114176. Epub 2024 Jun 28. J Pediatr. 2024. PMID: 38945446
Management of pulmonary aspergillosis in children: a systematic review.
Terlizzi V, Motisi MA, Pellegrino R, Galli L, Taccetti G, Chiappini E. Terlizzi V, et al. Among authors: taccetti g. Ital J Pediatr. 2023 Mar 28;49(1):39. doi: 10.1186/s13052-023-01440-9. Ital J Pediatr. 2023. PMID: 36978151 Free PMC article. Review.
The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus.
Gramegna A, Aliberti S, Calderazzo MA, Casciaro R, Ceruti C, Cimino G, Fabrizzi B, Lucanto C, Messore B, Pisi G, Taccetti G, Tarsia P, Blasi F, Cipolli M. Gramegna A, et al. Among authors: taccetti g. Respir Med. 2023 Dec;220:107455. doi: 10.1016/j.rmed.2023.107455. Epub 2023 Nov 3. Respir Med. 2023. PMID: 37926181 Free article.
One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes.
Castaldo A, Gelzo M, Iacotucci P, Longobardi A, Taccetti G, Terlizzi V, Carnovale V. Castaldo A, et al. Among authors: taccetti g. Front Mol Biosci. 2024 Jan 8;10:1327958. doi: 10.3389/fmolb.2023.1327958. eCollection 2023. Front Mol Biosci. 2024. PMID: 38259684 Free PMC article.
Microbiology of cystic fibrosis persons not chronically infected with P. aeruginosa: A quasi-experimental study on two different upper airways' sampling methods.
Dolce D, Ravenni N, Fevola C, Francalanci M, Bonomi P, Cavicchi MC, Galici V, Neri AS, Taccetti G, Terlizzi V, Innocenti D, Ferrari B, Bianchimani C, Camera E, Orioli T, Campana S. Dolce D, et al. Among authors: taccetti g. Heliyon. 2024 Feb 29;10(5):e26978. doi: 10.1016/j.heliyon.2024.e26978. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38449646 Free PMC article.
Corrigendum to "Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 years with Cystic Fibrosis and at Least one F508dek Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor". J Pediatr. 2024 Jun 28; 274:114176.
Terlizzi V, Fevola C, Presti S, Castaldo A, Daccò V, Claut L, Sepe A, Majo F, Casciaro R, Esposito I, Vitullo P, Salvi M, Troiani P, Ficili F, Parisi GF, Pantano S, Costa S, Leonetti G, Palladino N, Taccetti G, Bonomi P, Salvatore D. Terlizzi V, et al. Among authors: taccetti g. J Pediatr. 2024 Nov;274:114228. doi: 10.1016/j.jpeds.2024.114228. Epub 2024 Aug 28. J Pediatr. 2024. PMID: 39198099 Free article. No abstract available.
171 results